美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Global Partners Lp

42.80

-0.4100-0.95%

成交量：5.02萬

成交額：214.89萬

市值：14.55億

市盈率：20.57

高：43.64

開：43.11

低：42.50

收：43.21

52周最高：60.00

52周最低：39.70

股本：3,399.56萬

流通股本：2,767.42萬

量比：0.57

換手率：0.18%

股息：2.99

股息率：6.99%

每股收益(TTM):2.08

每股收益(LYR):2.45

淨資產收益率：13.77%

總資產收益率：3.98%

市淨率：2.40

市盈率(LYR):17.50

資料載入中...

總覽公司新聞資訊公告

登頂《Nature》主刊 | 信爾美®（瑪仕度肽注射液，GCG/GLP-1雙靶減重降糖藥物）兩項III期臨牀研究結果背靠背同步發表

昭衍新藥：公司具備OECD的GLP認證資格

Veru獲准將其試驗性減肥藥與GLP-1藥物聯合使用進行試驗

GLP-1賽道激戰正酣：雙靶點、口服藥引領迭代潮，千億市場掘金圖譜全解析

GLP-1賽道或再擴容！信達生物瑪仕度肽青少年Ib期臨牀研究達主要終點搶灘百億減重市場

中國藥企口服 GLP-1 超 20 億美元授權輝瑞；正大天晴全球首個 CDK2/4/6 抑制劑獲批上市｜Insight 新藥週報

丁香园 Insight 数据库

碧生源(00926)加碼投資ERX維持3%持股支持非GLP-1減肥療法創新研發

悦康藥業宋更申：GLP-1類藥物減肥或致抑鬱，被稱為「戒斷七情六慾的藥」

石藥集團(01093)：GLP-1/GIP受體雙偏向性激動多肽注射液在美國獲臨牀試驗批准

司美格魯肽等GLP-1藥物寫入WHO全球指南用於肥胖症治療

中國生物製藥(01177)：TQF3250「口服偏向型GLP-1受體激動劑」臨牀試驗申請獲NMPA、FDA批准

漢堡王準備迎接GLP-1的變化

司美格魯肽全球熱銷催生百億市場：國內30+企業激戰GLP-1賽道，2025年產能格局全解析

Grvt GLP 策略重新開放，資金上限提升至 750 萬美元

歌禮制藥-B(01672)選定其首款口服GLP-1R/GIPR/GCGR三靶點激動劑多肽ASC37進行臨牀開發

從注射到口服 GLP-1減肥藥進入下一時代

环球市场播报

禮來模式揭秘：GLP-1，AI 加速藥物發現，禮來如何突破「創新者窘境」？

海外独角兽

全球首個基礎胰島素GLP-1RA周製劑Kyinsu歐盟獲批

諾和諾德 GLP-1 折戟阿爾茨海默病，渤健 Leqembi 迎來競爭利好

派格生物首個產品獲批，GLP-1賽道已有16個玩家；復宏漢霖HLX43啓動II期臨牀，適應證為胰腺導管腺癌 | 掘金創新藥

每日经济新闻

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/GLP/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GLP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLP\",,,,,undefined,":{"symbol":"GLP","market":"US","secType":"STK","nameCN":"Global Partners Lp","latestPrice":42.8,"timestamp":1766437200000,"preClose":43.21,"halted":0,"volume":50183,"delay":0,"floatShares":27674174,"shares":33995563,"eps":2.080802,"marketStatus":"盤前交易","change":-0.41,"latestTime":"12-23 05:41:44 EST","open":43.11,"high":43.64,"low":42.5,"amount":2148905.3706,"amplitude":0.026383,"askPrice":68.05,"askSize":100,"bidPrice":40,"bidSize":3,"shortable":3,"etf":0,"ttmEps":2.080802,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1766500200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1127966400000,"exchange":"NYSE","adjPreClose":42.8,"dividendRate":0.06986,"postHourTrading":{"tag":"盘后","latestPrice":42.8,"preClose":42.8,"latestTime":"16:10 EST","volume":13205,"amount":565174,"timestamp":1766437803852},"volumeRatio":0.5671305444068204,"impliedVol":0.2302,"impliedVolPercentile":0.1486},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLP\",,,,,undefined,":{"symbol":"GLP","floatShares":27674174,"roa":"3.98%","roe":"13.77%","lyrEps":2.44604,"volumeRatio":0.5671305444068204,"shares":33995563,"dividePrice":2.99,"high":43.64,"amplitude":0.026383,"preClose":43.21,"low":42.5,"week52Low":39.7,"pbRate":"2.40","psRate":"0.08","week52High":60,"institutionHeld":0.4714,"latestPrice":42.8,"committee":-0.941748,"eps":2.080802,"divideRate":0.06986,"volume":50183,"delay":0,"ttmEps":2.080802,"open":43.11,"prevYearClose":46.55,"prevWeekClose":43.21,"prevMonthClose":43.98,"prevQuarterClose":48,"fiveDayClose":43.87,"twentyDayClose":42.02,"sixtyDayClose":49.99,"dividendPayoutRate":1.1692368072476331,"dividendFrequency":"Q","dividendGrowthYears":0,"dividendGrowthRate":-0.20278745644599305,"fiveYearAvgDividendRate":0.09217143297642297},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GLP\",params:#limit:5,,,undefined,":[{"date":"2025-11-10","symbol":"GLP","amount":0.755,"announcedDate":"2025-10-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-11-10","defaultRemindTime":1762785000000,"name":"Global Partners Lp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-14","payableDate":"2025-11-10","currency":"USD","dateTimestamp":1762750800000,"payDate":"2025-11-14"},{"market":"US","date":"2025-11-07","symbol":"GLP","fiscalQuarterEnding":"2025/09","expectedEps":1.09,"name":null,"time":"盤前","type":"earning","dateTimestamp":1762491600000,"reportTimeType":"pre","actualEps":0.66},{"date":"2025-08-08","symbol":"GLP","amount":0.75,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-08","defaultRemindTime":1754659800000,"name":"Global Partners Lp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-08-14","payableDate":"2025-08-08","currency":"USD","dateTimestamp":1754625600000,"payDate":"2025-08-14"},{"market":"US","date":"2025-08-07","symbol":"GLP","fiscalQuarterEnding":"2025/06","expectedEps":0.6,"name":null,"time":"盤前","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":0.55},{"date":"2025-05-09","symbol":"GLP","amount":0.745,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-09","defaultRemindTime":1746797400000,"name":"Global Partners Lp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-15","payableDate":"2025-05-09","currency":"USD","dateTimestamp":1746763200000,"payDate":"2025-05-15"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GLP\",market:\"US\",,,undefined,":[{"executeDate":"2016-02-08","recordDate":"2016-02-10","paymentDate":"2016-02-16","value":0.4625,"currency":"USD"},{"executeDate":"2016-05-04","recordDate":"2016-05-06","paymentDate":"2016-05-16","value":0.4625,"currency":"USD"},{"executeDate":"2016-08-04","recordDate":"2016-08-08","paymentDate":"2016-08-12","value":0.4625,"currency":"USD"},{"executeDate":"2016-11-04","recordDate":"2016-11-08","paymentDate":"2016-11-14","value":0.4625,"currency":"USD"},{"executeDate":"2017-02-07","recordDate":"2017-02-09","paymentDate":"2017-02-14","value":0.4625,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GLP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":2,"updateTime":1741237200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GLP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GLP","date":"2025-12-19","current":20.568992,"percent":0.846709,"low":2.771386,"twenty":4.440923,"median":11.01485,"eighty":17.334253,"high":29.34912,"avg":11.680806,"sd":6.381541,"marketCap":1433877315},"quantilePoints":[{"date":"2020-12-24","current":6.048705,"twenty":6.167844,"median":7.82096,"eighty":11.115597,"marketCap":579278410},{"date":"2020-12-31","current":5.934444,"twenty":6.167844,"median":7.817068,"eighty":11.101741,"marketCap":568335725},{"date":"2021-01-08","current":6.062987,"twenty":6.149862,"median":7.795662,"eighty":11.084422,"marketCap":580646246},{"date":"2021-01-15","current":6.216526,"twenty":6.149862,"median":7.785585,"eighty":11.084422,"marketCap":595350479},{"date":"2021-01-22","current":6.705707,"twenty":6.149862,"median":7.780094,"eighty":11.074992,"marketCap":642198851},{"date":"2021-01-29","current":7.180605,"twenty":6.149862,"median":7.776202,"eighty":11.068208,"marketCap":687679388},{"date":"2021-02-05","current":7.284155,"twenty":6.149862,"median":7.768418,"eighty":11.06411,"marketCap":697596196},{"date":"2021-02-12","current":6.934229,"twenty":6.163202,"median":7.760634,"eighty":11.053134,"marketCap":664084222},{"date":"2021-02-19","current":7.112763,"twenty":6.167321,"median":7.75285,"eighty":11.04396,"marketCap":681182168},{"date":"2021-02-26","current":7.202029,"twenty":6.167844,"median":7.741174,"eighty":11.038761,"marketCap":689731141},{"date":"2021-03-05","current":6.896217,"twenty":6.167844,"median":7.718575,"eighty":11.032407,"marketCap":695214499},{"date":"2021-03-12","current":7.842623,"twenty":6.167844,"median":7.698362,"eighty":11.017031,"marketCap":790622686},{"date":"2021-03-19","current":7.720506,"twenty":6.167844,"median":7.718575,"eighty":11.007626,"marketCap":778311953},{"date":"2021-03-26","current":7.411822,"twenty":6.167844,"median":7.69367,"eighty":11.00501,"marketCap":747193153},{"date":"2021-04-01","current":7.320234,"twenty":6.167844,"median":7.686686,"eighty":10.988222,"marketCap":737960103},{"date":"2021-04-09","current":7.3779,"twenty":6.167844,"median":7.67501,"eighty":10.954813,"marketCap":743773505},{"date":"2021-04-16","current":7.510194,"twenty":6.168749,"median":7.659442,"eighty":10.940212,"marketCap":757110133},{"date":"2021-04-23","current":7.364332,"twenty":6.170107,"median":7.594997,"eighty":10.930856,"marketCap":742405645},{"date":"2021-04-30","current":8.185229,"twenty":6.171613,"median":7.641929,"eighty":10.912383,"marketCap":825161134},{"date":"2021-05-07","current":9.181725,"twenty":6.178654,"median":7.67501,"eighty":10.905455,"marketCap":849502414},{"date":"2021-05-14","current":8.749253,"twenty":6.185826,"median":7.686686,"eighty":10.905455,"marketCap":809489619},{"date":"2021-05-21","current":9.203903,"twenty":6.185826,"median":7.690578,"eighty":10.897433,"marketCap":851554353},{"date":"2021-05-28","current":9.407203,"twenty":6.185826,"median":7.712361,"eighty":10.877257,"marketCap":870363786},{"date":"2021-06-04","current":9.706607,"twenty":6.189262,"median":7.720506,"eighty":10.864653,"marketCap":898064952},{"date":"2021-06-11","current":10.061456,"twenty":6.203126,"median":7.741174,"eighty":10.858681,"marketCap":930895963},{"date":"2021-06-18","current":9.603109,"twenty":6.203644,"median":7.748958,"eighty":10.836624,"marketCap":888489240},{"date":"2021-06-25","current":9.680732,"twenty":6.203808,"median":7.760634,"eighty":10.817799,"marketCap":895671024},{"date":"2021-07-02","current":9.658554,"twenty":6.203808,"median":7.768418,"eighty":10.809851,"marketCap":893619086},{"date":"2021-07-09","current":9.31849,"twenty":6.203808,"median":7.778148,"eighty":10.796921,"marketCap":862156033},{"date":"2021-07-16","current":8.963641,"twenty":6.213362,"median":7.780094,"eighty":10.785892,"marketCap":829325022},{"date":"2021-07-23","current":9.495915,"twenty":6.213362,"median":7.785616,"eighty":10.763835,"marketCap":878571539},{"date":"2021-07-30","current":9.909906,"twenty":6.216526,"median":7.795662,"eighty":10.752807,"marketCap":916874385},{"date":"2021-08-06","current":29.34912,"twenty":6.22179,"median":7.817068,"eighty":10.752807,"marketCap":823536295},{"date":"2021-08-13","current":26.023372,"twenty":6.22179,"median":7.822906,"eighty":10.813084,"marketCap":730215805},{"date":"2021-08-20","current":24.554702,"twenty":6.22179,"median":7.83069,"eighty":10.865043,"marketCap":689004931},{"date":"2021-08-27","current":24.530426,"twenty":6.22179,"median":7.834582,"eighty":10.905455,"marketCap":688323760},{"date":"2021-09-03","current":25.100901,"twenty":6.22179,"median":7.842494,"eighty":10.964493,"marketCap":704331289},{"date":"2021-09-10","current":24.275533,"twenty":6.228856,"median":7.848204,"eighty":11.013201,"marketCap":681171460},{"date":"2021-09-17","current":25.198003,"twenty":6.230622,"median":7.85015,"eighty":11.053134,"marketCap":707055975},{"date":"2021-09-24","current":24.894559,"twenty":6.230772,"median":7.876969,"eighty":11.084422,"marketCap":698541332},{"date":"2021-10-01","current":26.047647,"twenty":6.233421,"median":7.883329,"eighty":11.141011,"marketCap":730896976},{"date":"2021-10-08","current":26.897291,"twenty":6.234318,"median":7.892962,"eighty":11.19642,"marketCap":754737977},{"date":"2021-10-15","current":26.836602,"twenty":6.236185,"median":7.896854,"eighty":11.246674,"marketCap":753035049},{"date":"2021-10-22","current":28.632991,"twenty":6.237348,"median":7.914368,"eighty":11.269162,"marketCap":803441737},{"date":"2021-10-29","current":28.329547,"twenty":6.237865,"median":7.935774,"eighty":11.303569,"marketCap":794927093},{"date":"2021-11-05","current":18.151279,"twenty":6.239408,"median":7.94745,"eighty":11.328048,"marketCap":776838422},{"date":"2021-11-12","current":18.191189,"twenty":6.239772,"median":7.988112,"eighty":11.346522,"marketCap":778546510},{"date":"2021-11-19","current":18.773882,"twenty":6.239772,"median":8.014118,"eighty":11.360961,"marketCap":803484595},{"date":"2021-11-26","current":18.694061,"twenty":6.239772,"median":8.035981,"eighty":11.378852,"marketCap":800068419},{"date":"2021-12-03","current":18.103386,"twenty":6.239772,"median":8.105729,"eighty":11.403489,"marketCap":774788716},{"date":"2021-12-10","current":18.430652,"twenty":6.240495,"median":8.179783,"eighty":11.427136,"marketCap":788795038},{"date":"2021-12-17","current":18.550383,"twenty":6.243048,"median":8.213544,"eighty":11.470285,"marketCap":793919302},{"date":"2021-12-23","current":17.991637,"twenty":6.244429,"median":8.252749,"eighty":11.474686,"marketCap":770006070},{"date":"2021-12-31","current":18.749936,"twenty":6.244429,"median":8.284603,"eighty":11.575574,"marketCap":802459742},{"date":"2022-01-07","current":20.051017,"twenty":6.24581,"median":8.291955,"eighty":11.616705,"marketCap":858143411},{"date":"2022-01-14","current":21.152545,"twenty":6.248234,"median":8.320498,"eighty":11.690231,"marketCap":905286640},{"date":"2022-01-21","current":20.146802,"twenty":6.249277,"median":8.363015,"eighty":11.729858,"marketCap":862242822},{"date":"2022-01-28","current":21.392008,"twenty":6.251718,"median":8.365465,"eighty":11.776801,"marketCap":915535168},{"date":"2022-02-04","current":21.85497,"twenty":6.254157,"median":8.433466,"eighty":11.837284,"marketCap":935348988},{"date":"2022-02-11","current":21.559632,"twenty":6.257754,"median":8.47328,"eighty":11.938846,"marketCap":922709137},{"date":"2022-02-18","current":20.945011,"twenty":6.257851,"median":8.48054,"eighty":12.432666,"marketCap":896404582},{"date":"2022-02-25","current":20.529942,"twenty":6.258237,"median":8.487891,"eighty":12.775373,"marketCap":878640467},{"date":"2022-03-04","current":15.348683,"twenty":6.268592,"median":8.571294,"eighty":13.121553,"marketCap":878174885},{"date":"2022-03-11","current":15.504022,"twenty":6.275496,"median":8.601399,"eighty":13.154839,"marketCap":887062603},{"date":"2022-03-18","current":15.940166,"twenty":6.275736,"median":8.649704,"eighty":13.201441,"marketCap":912016580},{"date":"2022-03-25","current":16.890123,"twenty":6.275736,"median":8.669307,"eighty":13.248042,"marketCap":966368393},{"date":"2022-04-01","current":16.214996,"twenty":6.275736,"median":8.68891,"eighty":13.261356,"marketCap":927741004},{"date":"2022-04-08","current":16.752708,"twenty":6.275736,"median":8.726599,"eighty":13.281328,"marketCap":958506181},{"date":"2022-04-14","current":16.573471,"twenty":6.275736,"median":8.736337,"eighty":13.3013,"marketCap":948251122},{"date":"2022-04-22","current":16.011861,"twenty":6.276168,"median":8.777122,"eighty":13.329261,"marketCap":916118604},{"date":"2022-04-29","current":15.743005,"twenty":6.281175,"median":8.797306,"eighty":13.342575,"marketCap":900736015},{"date":"2022-05-06","current":9.804164,"twenty":6.2824,"median":8.848712,"eighty":13.349233,"marketCap":897659497},{"date":"2022-05-13","current":9.69216,"twenty":6.2824,"median":8.9103,"eighty":13.347901,"marketCap":887404438},{"date":"2022-05-20","current":10.270852,"twenty":6.291454,"median":8.930374,"eighty":13.347901,"marketCap":940388910},{"date":"2022-05-27","current":11.163158,"twenty":6.293718,"median":8.972794,"eighty":13.342575,"marketCap":1022087547},{"date":"2022-06-03","current":10.868211,"twenty":6.294536,"median":8.995202,"eighty":13.341244,"marketCap":995082558},{"date":"2022-06-10","current":10.244717,"twenty":6.297672,"median":9.026396,"eighty":13.341244,"marketCap":937996063},{"date":"2022-06-17","current":7.754474,"twenty":6.299555,"median":9.016925,"eighty":13.33725,"marketCap":709991918},{"date":"2022-06-24","current":8.613179,"twenty":6.299659,"median":8.99034,"eighty":13.331924,"marketCap":788614037},{"date":"2022-07-01","current":8.814788,"twenty":6.299659,"median":8.977241,"eighty":13.322603,"marketCap":807073143},{"date":"2022-07-08","current":8.900658,"twenty":6.299659,"median":8.963641,"eighty":13.313284,"marketCap":814935355},{"date":"2022-07-15","current":8.867057,"twenty":6.299659,"median":8.92485,"eighty":13.306626,"marketCap":811858837},{"date":"2022-07-22","current":9.561487,"twenty":6.300172,"median":8.963641,"eighty":13.3013,"marketCap":875440203},{"date":"2022-07-29","current":10.371656,"twenty":6.303369,"median":8.980096,"eighty":13.299969,"marketCap":949618463},{"date":"2022-08-05","current":3.850073,"twenty":6.303369,"median":8.997729,"eighty":13.29198,"marketCap":927520968},{"date":"2022-08-12","current":4.016293,"twenty":6.299659,"median":8.972794,"eighty":13.281328,"marketCap":967565231},{"date":"2022-08-19","current":3.999245,"twenty":6.293991,"median":8.937993,"eighty":13.278687,"marketCap":963458127},{"date":"2022-08-26","current":3.899797,"twenty":6.2824,"median":8.919306,"eighty":13.268103,"marketCap":939500021},{"date":"2022-09-02","current":4.077383,"twenty":6.275736,"median":8.9103,"eighty":13.268014,"marketCap":982282354},{"date":"2022-09-09","current":4.169728,"twenty":6.275496,"median":8.900658,"eighty":13.268014,"marketCap":1004529167},{"date":"2022-09-16","current":4.014873,"twenty":6.257754,"median":8.857885,"eighty":13.261356,"marketCap":967222973},{"date":"2022-09-23","current":3.607134,"twenty":6.247881,"median":8.814788,"eighty":13.254699,"marketCap":868994737},{"date":"2022-09-30","current":3.51621,"twenty":6.240977,"median":8.791187,"eighty":13.254699,"marketCap":847090183},{"date":"2022-10-07","current":3.916845,"twenty":6.239772,"median":8.777122,"eighty":13.248042,"marketCap":943607125},{"date":"2022-10-14","current":3.740679,"twenty":6.236636,"median":8.755886,"eighty":13.248042,"marketCap":901167051},{"date":"2022-10-21","current":4.087328,"twenty":6.230622,"median":8.734756,"eighty":13.241384,"marketCap":984678164},{"date":"2022-10-28","current":4.250707,"twenty":6.22179,"median":8.716798,"eighty":13.234727,"marketCap":1024037910},{"date":"2022-11-04","current":3.449288,"twenty":6.213362,"median":8.68891,"eighty":13.208098,"marketCap":1095762902},{"date":"2022-11-11","current":3.301892,"twenty":6.203808,"median":8.669307,"eighty":13.201441,"marketCap":1048938349},{"date":"2022-11-18","current":3.311575,"twenty":6.185826,"median":8.649704,"eighty":13.194783,"marketCap":1052014414},{"date":"2022-11-25","current":3.399797,"twenty":6.17312,"median":8.639313,"eighty":13.17348,"marketCap":1080040789},{"date":"2022-12-02","current":3.385811,"twenty":6.167844,"median":8.62969,"eighty":13.162828,"marketCap":1075597583},{"date":"2022-12-09","current":3.518145,"twenty":6.167844,"median":8.601399,"eighty":13.156171,"marketCap":1117637146},{"date":"2022-12-16","current":3.574091,"twenty":6.149862,"median":8.577106,"eighty":13.154839,"marketCap":1135409969},{"date":"2022-12-23","current":3.865656,"twenty":6.146266,"median":8.549709,"eighty":13.144188,"marketCap":1228033720},{"date":"2022-12-30","current":3.740853,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1188386653},{"date":"2023-01-06","current":3.441757,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1093370406},{"date":"2023-01-13","current":3.612823,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1147714231},{"date":"2023-01-20","current":3.620354,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1150106726},{"date":"2023-01-27","current":3.857048,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1225299440},{"date":"2023-02-03","current":4.130323,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1312112845},{"date":"2023-02-10","current":3.93774,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1250933319},{"date":"2023-02-17","current":3.875339,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1231109786},{"date":"2023-02-24","current":3.718259,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1181209167},{"date":"2023-03-03","current":3.363192,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1194165378},{"date":"2023-03-10","current":3.211151,"twenty":6.113691,"median":8.482899,"eighty":13.133536,"marketCap":1140180220},{"date":"2023-03-17","current":2.830086,"twenty":6.097582,"median":8.463126,"eighty":13.133536,"marketCap":1004875645},{"date":"2023-03-24","current":2.875313,"twenty":6.070129,"median":8.365465,"eighty":13.133536,"marketCap":1020934521},{"date":"2023-03-31","current":2.985014,"twenty":6.034422,"median":8.291955,"eighty":13.130873,"marketCap":1059885838},{"date":"2023-04-06","current":2.892634,"twenty":6.016569,"median":8.274802,"eighty":13.130873,"marketCap":1027084729},{"date":"2023-04-14","current":2.896483,"twenty":5.960153,"median":8.185229,"eighty":13.133536,"marketCap":1028451442},{"date":"2023-04-20","current":2.925352,"twenty":5.879004,"median":8.105729,"eighty":13.133536,"marketCap":1038701788},{"date":"2023-04-28","current":2.932088,"twenty":5.726233,"median":7.998046,"eighty":13.136199,"marketCap":1041093536},{"date":"2023-05-05","current":2.771386,"twenty":5.536171,"median":7.943558,"eighty":13.136199,"marketCap":984033273},{"date":"2023-05-12","current":2.975648,"twenty":5.442294,"median":7.932539,"eighty":13.136199,"marketCap":1050433502},{"date":"2023-05-19","current":3.089052,"twenty":5.341054,"median":7.932539,"eighty":13.136199,"marketCap":1090466310},{"date":"2023-05-26","current":2.874844,"twenty":5.253436,"median":7.932539,"eighty":13.136199,"marketCap":1014848784},{"date":"2023-06-02","current":2.846736,"twenty":5.130475,"median":7.932539,"eighty":13.136199,"marketCap":1004926122},{"date":"2023-06-09","current":3.07839,"twenty":5.004569,"median":7.932539,"eighty":13.136199,"marketCap":1086702542},{"date":"2023-06-16","current":3.058036,"twenty":4.918423,"median":7.932539,"eighty":13.136199,"marketCap":1079517166},{"date":"2023-06-23","current":2.916523,"twenty":4.864674,"median":7.935774,"eighty":13.138862,"marketCap":1029561696},{"date":"2023-06-30","current":2.952386,"twenty":4.815342,"median":7.93772,"eighty":13.141525,"marketCap":1042221644},{"date":"2023-07-07","current":2.944631,"twenty":4.771165,"median":7.93772,"eighty":13.141525,"marketCap":1039484358},{"date":"2023-07-14","current":3.066759,"twenty":4.749076,"median":7.93772,"eighty":13.141525,"marketCap":1082596613},{"date":"2023-07-21","current":3.116192,"twenty":4.697536,"median":7.93772,"eighty":13.141525,"marketCap":1100046811},{"date":"2023-07-28","current":3.215057,"twenty":4.671766,"median":7.93772,"eighty":13.141525,"marketCap":1134947207},{"date":"2023-08-04","current":3.279998,"twenty":4.616544,"median":7.93772,"eighty":13.141525,"marketCap":1157871978},{"date":"2023-08-11","current":4.645552,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1075069076},{"date":"2023-08-18","current":4.647031,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1075411237},{"date":"2023-08-25","current":4.663295,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1079175005},{"date":"2023-09-01","current":4.624853,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1070278826},{"date":"2023-09-08","current":4.647031,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1075411237},{"date":"2023-09-15","current":4.775663,"twenty":4.570147,"median":7.93772,"eighty":13.141525,"marketCap":1105179222},{"date":"2023-09-22","current":4.867332,"twenty":4.570147,"median":7.93772,"eighty":13.141525,"marketCap":1126393189},{"date":"2023-09-29","current":5.173389,"twenty":4.570147,"median":7.93772,"eighty":13.141525,"marketCap":1197220464},{"date":"2023-10-06","current":4.475521,"twenty":4.542915,"median":7.93772,"eighty":13.141525,"marketCap":1035720590},{"date":"2023-10-13","current":4.511006,"twenty":4.484012,"median":7.93772,"eighty":13.141525,"marketCap":1043932448},{"date":"2023-10-20","current":4.482914,"twenty":4.482914,"median":7.93772,"eighty":13.141525,"marketCap":1037431394},{"date":"2023-10-27","current":4.534662,"twenty":4.467537,"median":7.94745,"eighty":13.149513,"marketCap":1049407020},{"date":"2023-11-03","current":4.904296,"twenty":4.458666,"median":7.94745,"eighty":13.149513,"marketCap":1134947207},{"date":"2023-11-10","current":7.439549,"twenty":4.458666,"median":7.935774,"eighty":13.149513,"marketCap":1088071185},{"date":"2023-11-17","current":7.820894,"twenty":4.458666,"median":7.896854,"eighty":13.149513,"marketCap":1143844827},{"date":"2023-11-24","current":7.993518,"twenty":4.458666,"median":7.896854,"eighty":13.149513,"marketCap":1169092039},{"date":"2023-12-01","current":8.460278,"twenty":4.458666,"median":7.896854,"eighty":13.149513,"marketCap":1237357955},{"date":"2023-12-08","current":8.743603,"twenty":4.459848,"median":7.902692,"eighty":13.146851,"marketCap":1278795691},{"date":"2023-12-15","current":8.690189,"twenty":4.459848,"median":7.902692,"eighty":13.146851,"marketCap":1270983658},{"date":"2023-12-22","current":9.616802,"twenty":4.459848,"median":7.934448,"eighty":13.146851,"marketCap":1406505433},{"date":"2023-12-29","current":9.686473,"twenty":4.4563,"median":7.940074,"eighty":13.154839,"marketCap":1416695040},{"date":"2024-01-05","current":9.75382,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1426544994},{"date":"2024-01-12","current":9.809556,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1434696679},{"date":"2024-01-19","current":10.16023,"twenty":4.448612,"median":7.939666,"eighty":13.154839,"marketCap":1485984368},{"date":"2024-01-26","current":10.740814,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1570897761},{"date":"2024-02-02","current":10.601474,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1550518547},{"date":"2024-02-09","current":10.963759,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1603504503},{"date":"2024-02-16","current":11.124,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1626940600},{"date":"2024-02-23","current":10.647921,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1557311618},{"date":"2024-03-01","current":11.10678,"twenty":4.4563,"median":7.940074,"eighty":13.154839,"marketCap":1583804596},{"date":"2024-03-08","current":11.32675,"twenty":4.4563,"median":7.94745,"eighty":13.154839,"marketCap":1615171958},{"date":"2024-03-15","current":10.799262,"twenty":4.4563,"median":7.990262,"eighty":13.154839,"marketCap":1539953125},{"date":"2024-03-22","current":11.659401,"twenty":4.4563,"median":8.049544,"eighty":13.154839,"marketCap":1662607257},{"date":"2024-03-28","current":10.571159,"twenty":4.4563,"median":8.239503,"eighty":13.154839,"marketCap":1507426062},{"date":"2024-04-05","current":10.811142,"twenty":4.452456,"median":8.461702,"eighty":13.154839,"marketCap":1541647243},{"date":"2024-04-12","current":11.186562,"twenty":4.452456,"median":8.566313,"eighty":13.154839,"marketCap":1595181367},{"date":"2024-04-19","current":10.81827,"twenty":4.452456,"median":8.624771,"eighty":13.154839,"marketCap":1542663714},{"date":"2024-04-26","current":11.245964,"twenty":4.4563,"median":8.639313,"eighty":13.154839,"marketCap":1603651956},{"date":"2024-05-03","current":11.324374,"twenty":4.4563,"median":8.690189,"eighty":13.154839,"marketCap":1614833134},{"date":"2024-05-10","current":14.682959,"twenty":4.4563,"median":8.734756,"eighty":13.168154,"marketCap":1565364893},{"date":"2024-05-17","current":13.78037,"twenty":4.4563,"median":8.734756,"eighty":13.224197,"marketCap":1469138999},{"date":"2024-05-24","current":14.166489,"twenty":4.4563,"median":8.734756,"eighty":13.241384,"marketCap":1510303519},{"date":"2024-05-31","current":15.403069,"twenty":4.4563,"median":8.734756,"eighty":13.248042,"marketCap":1642136538},{"date":"2024-06-07","current":15.399881,"twenty":4.4563,"median":8.734756,"eighty":13.254699,"marketCap":1641796762},{"date":"2024-06-14","current":15.042931,"twenty":4.4563,"median":8.734756,"eighty":13.254699,"marketCap":1603741870},{"date":"2024-06-21","current":14.389583,"twenty":4.452456,"median":8.72747,"eighty":13.257384,"marketCap":1534087827},{"date":"2024-06-28","current":14.542562,"twenty":4.452456,"median":8.72747,"eighty":13.270766,"marketCap":1550397066},{"date":"2024-07-05","current":14.395957,"twenty":4.452456,"median":8.72747,"eighty":13.285322,"marketCap":1534767378},{"date":"2024-07-12","current":13.586443,"twenty":4.452456,"median":8.72747,"eighty":13.285322,"marketCap":1448464320},{"date":"2024-07-19","current":12.767369,"twenty":4.452456,"median":8.72747,"eighty":13.228966,"marketCap":1361141934},{"date":"2024-07-26","current":12.910786,"twenty":4.452456,"median":8.72747,"eighty":13.052045,"marketCap":1376431846},{"date":"2024-08-02","current":13.302795,"twenty":4.452456,"median":8.72747,"eighty":12.924809,"marketCap":1418224272},{"date":"2024-08-09","current":12.449802,"twenty":4.452456,"median":8.72747,"eighty":12.75462,"marketCap":1335540014},{"date":"2024-08-16","current":13.196601,"twenty":4.452456,"median":8.72747,"eighty":12.789678,"marketCap":1415652134},{"date":"2024-08-23","current":13.473893,"twenty":4.452456,"median":8.72747,"eighty":13.02799,"marketCap":1445398406},{"date":"2024-08-30","current":14.204937,"twenty":4.452456,"median":8.72747,"eighty":13.191559,"marketCap":1523820396},{"date":"2024-09-06","current":13.316341,"twenty":4.452456,"median":8.72747,"eighty":13.222287,"marketCap":1428497115},{"date":"2024-09-13","current":13.558971,"twenty":4.452456,"median":8.72747,"eighty":13.305504,"marketCap":1454525103},{"date":"2024-09-20","current":14.226994,"twenty":4.452456,"median":8.72747,"eighty":13.395117,"marketCap":1526186577},{"date":"2024-09-27","current":14.085197,"twenty":4.452456,"median":8.72747,"eighty":13.544476,"marketCap":1510975415},{"date":"2024-10-04","current":14.976944,"twenty":4.452456,"median":8.72747,"eighty":13.679972,"marketCap":1606636722},{"date":"2024-10-11","current":14.803637,"twenty":4.452456,"median":8.72747,"eighty":13.85562,"marketCap":1588045302},{"date":"2024-10-18","current":14.529495,"twenty":4.452456,"median":8.72747,"eighty":14.019655,"marketCap":1558637056},{"date":"2024-10-25","current":14.772126,"twenty":4.452456,"median":8.72747,"eighty":14.168401,"marketCap":1584665044},{"date":"2024-11-01","current":14.778428,"twenty":4.452456,"median":8.72747,"eighty":14.27768,"marketCap":1585341095},{"date":"2024-11-08","current":13.141823,"twenty":4.452456,"median":8.73918,"eighty":14.377354,"marketCap":1640493731},{"date":"2024-11-15","current":13.379586,"twenty":4.452456,"median":8.78252,"eighty":14.377354,"marketCap":1670173717},{"date":"2024-11-22","current":14.322533,"twenty":4.452456,"median":8.81344,"eighty":14.377354,"marketCap":1787881840},{"date":"2024-11-29","current":15.251971,"twenty":4.452456,"median":8.883858,"eighty":14.399781,"marketCap":1903903601},{"date":"2024-12-06","current":15.273586,"twenty":4.452456,"median":8.934183,"eighty":14.482822,"marketCap":1906601781},{"date":"2024-12-13","current":14.4198,"twenty":4.452456,"median":9.012663,"eighty":14.537463,"marketCap":1800023652},{"date":"2024-12-20","current":12.93378,"twenty":4.452456,"median":9.090449,"eighty":14.537463,"marketCap":1614523744},{"date":"2024-12-27","current":12.995923,"twenty":4.452456,"median":9.19602,"eighty":14.537463,"marketCap":1622281013},{"date":"2025-01-03","current":12.766265,"twenty":4.452456,"median":9.268408,"eighty":14.537463,"marketCap":1593612846},{"date":"2025-01-10","current":12.631172,"twenty":4.448612,"median":9.31881,"eighty":14.538738,"marketCap":1576749218},{"date":"2025-01-17","current":14.282006,"twenty":4.448612,"median":9.382279,"eighty":14.538738,"marketCap":1782822752},{"date":"2025-01-24","current":13.892938,"twenty":4.448612,"median":9.455255,"eighty":14.538738,"marketCap":1734255503},{"date":"2025-01-31","current":14.63865,"twenty":4.448612,"median":9.481129,"eighty":14.558635,"marketCap":1827342730},{"date":"2025-02-07","current":15.684268,"twenty":4.448612,"median":9.514397,"eighty":14.63454,"marketCap":1957867210},{"date":"2025-02-14","current":15.462716,"twenty":4.448612,"median":9.568033,"eighty":14.675959,"marketCap":1930210860},{"date":"2025-02-21","current":15.732902,"twenty":4.448612,"median":9.580931,"eighty":14.694621,"marketCap":1963938116},{"date":"2025-02-28","current":20.937616,"twenty":4.448612,"median":9.626092,"eighty":14.774647,"marketCap":1933567942},{"date":"2025-03-07","current":19.49754,"twenty":4.444767,"median":9.675026,"eighty":14.838928,"marketCap":1800578330},{"date":"2025-03-14","current":19.960552,"twenty":4.444767,"median":9.675026,"eighty":14.901539,"marketCap":1843337016},{"date":"2025-03-21","current":19.362647,"twenty":4.444767,"median":9.689317,"eighty":15.017908,"marketCap":1788121076},{"date":"2025-03-28","current":19.698057,"twenty":4.444767,"median":9.708699,"eighty":15.110765,"marketCap":1819095871},{"date":"2025-04-04","current":17.87153,"twenty":4.444767,"median":9.75606,"eighty":15.125044,"marketCap":1650417909},{"date":"2025-04-11","current":17.576223,"twenty":4.448612,"median":9.799015,"eighty":15.243459,"marketCap":1623146621},{"date":"2025-04-17","current":18.509538,"twenty":4.448612,"median":9.802712,"eighty":15.283315,"marketCap":1709337357},{"date":"2025-04-25","current":18.910572,"twenty":4.444767,"median":9.80686,"eighty":15.360398,"marketCap":1746372438},{"date":"2025-05-02","current":18.710055,"twenty":4.444767,"median":9.80686,"eighty":15.401794,"marketCap":1727854897},{"date":"2025-05-09","current":14.05872,"twenty":4.444767,"median":9.80686,"eighty":15.43196,"marketCap":1621799891},{"date":"2025-05-16","current":14.406029,"twenty":4.444767,"median":9.80686,"eighty":15.43196,"marketCap":1661865116},{"date":"2025-05-23","current":14.373925,"twenty":4.444767,"median":9.80686,"eighty":15.43196,"marketCap":1658161608},{"date":"2025-05-30","current":15.450609,"twenty":4.444767,"median":9.80686,"eighty":15.444645,"marketCap":1782366767},{"date":"2025-06-06","current":15.621074,"twenty":4.444767,"median":9.80686,"eighty":15.514776,"marketCap":1802031456},{"date":"2025-06-13","current":16.520424,"twenty":4.444767,"median":9.80686,"eighty":15.572999,"marketCap":1905779645},{"date":"2025-06-20","current":16.170677,"twenty":4.440923,"median":9.804164,"eighty":15.627805,"marketCap":1865433127},{"date":"2025-06-27","current":15.57111,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1796267668},{"date":"2025-07-03","current":15.479999,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1785757230},{"date":"2025-07-11","current":15.432974,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1780332488},{"date":"2025-07-18","current":14.992116,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1729475533},{"date":"2025-07-25","current":15.333047,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1768804912},{"date":"2025-08-01","current":15.430035,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1779993442},{"date":"2025-08-08","current":17.700627,"twenty":4.440923,"median":9.82349,"eighty":15.67238,"marketCap":1703526003},{"date":"2025-08-15","current":17.97186,"twenty":4.440923,"median":9.917298,"eighty":15.726991,"marketCap":1729629785},{"date":"2025-08-22","current":17.975383,"twenty":4.440923,"median":9.97212,"eighty":15.765277,"marketCap":1729968795},{"date":"2025-08-29","current":18.669318,"twenty":4.440923,"median":10.032501,"eighty":15.848057,"marketCap":1796753795},{"date":"2025-09-05","current":18.391039,"twenty":4.437079,"median":10.161405,"eighty":15.873833,"marketCap":1769971993},{"date":"2025-09-12","current":18.229004,"twenty":4.440923,"median":10.244717,"eighty":15.951577,"marketCap":1754377526},{"date":"2025-09-19","current":17.911977,"twenty":4.440923,"median":10.348339,"eighty":16.07924,"marketCap":1723866612},{"date":"2025-09-26","current":17.668924,"twenty":4.440923,"median":10.483035,"eighty":16.238322,"marketCap":1700474912},{"date":"2025-10-03","current":16.622738,"twenty":4.440923,"median":10.565798,"eighty":16.310589,"marketCap":1599788897},{"date":"2025-10-10","current":15.678704,"twenty":4.440923,"median":10.601474,"eighty":16.329708,"marketCap":1508934177},{"date":"2025-10-17","current":15.460308,"twenty":4.440923,"median":10.638631,"eighty":16.329708,"marketCap":1487915548},{"date":"2025-10-24","current":16.192991,"twenty":4.440923,"median":10.724558,"eighty":16.329708,"marketCap":1558429659},{"date":"2025-10-31","current":15.978118,"twenty":4.440923,"median":10.745006,"eighty":16.329708,"marketCap":1537750040},{"date":"2025-11-07","current":15.678704,"twenty":4.440923,"median":10.777877,"eighty":16.329708,"marketCap":1508934177},{"date":"2025-11-14","current":18.215203,"twenty":4.440923,"median":10.808766,"eighty":16.403793,"marketCap":1432862540},{"date":"2025-11-21","current":18.438808,"twenty":4.440923,"median":10.856288,"eighty":16.560326,"marketCap":1450451976},{"date":"2025-11-28","current":18.911819,"twenty":4.440923,"median":10.868211,"eighty":16.63112,"marketCap":1487660399},{"date":"2025-12-05","current":19.647135,"twenty":4.440923,"median":10.912667,"eighty":16.757487,"marketCap":1545502583},{"date":"2025-12-12","current":19.023621,"twenty":4.440923,"median":10.960835,"eighty":17.137473,"marketCap":1496455117},{"date":"2025-12-19","current":18.228104,"twenty":4.440923,"median":11.01485,"eighty":17.334253,"marketCap":1433877315}],"updateTime":1766479586465},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GLP\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2592442959","title":"登頂《Nature》主刊 | 信爾美®（瑪仕度肽注射液，GCG/GLP-1雙靶減重降糖藥物）兩項III期臨牀研究結果背靠背同步發表","url":"https://stock-news.laohu8.com/highlight/detail?id=2592442959","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592442959?lang=zh_tw&edition=fundamental","pubTime":"2025-12-18 08:00","pubTimestamp":1766016000,"startTime":"0","endTime":"0","summary":"此次论文通过《自然》加速预览机制得以快速上线，再次印证国际顶级期刊对于玛仕度肽两项重磅研究的认可。信达生物制药集团综合管线首席研发官钱镭博士表示：\"信尔美是全球首个获批上市的GCG/GLP-1双靶药物，目前减重和糖尿病适应症均已获批。继其减重注册研究今年五月份发表于《新英格兰杂志》后，本次两项降糖注册研究DREAMS-1和DREAMS-2的成果再次以背靠背形式同步登上《自然》杂志，并以加速预览形式发表。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4849560_ZH49560_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2488822045.USD","LU2097828805.USD","LU0455707207.USD","LU0502904849.HKD","LU2097828631.EUR","BK4144","BK4134","LU1969619763.USD","01801","BK4139","LU2097828714.EUR","GLP","LU2097828474.EUR","BK1589","III","LU2242644610.SGD","BK1161","IVBIY","BK4590","BK1583","LU2328871848.SGD","LU2097828557.USD","HK0000165453.HKD"],"gpt_icon":0},{"id":"2592163639","title":"昭衍新藥：公司具備OECD的GLP認證資格","url":"https://stock-news.laohu8.com/highlight/detail?id=2592163639","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592163639?lang=zh_tw&edition=fundamental","pubTime":"2025-12-17 22:10","pubTimestamp":1765980600,"startTime":"0","endTime":"0","summary":"证券日报网讯 12月17日，昭衍新药在互动平台回答投资者提问时表示，公司具备OECD的GLP认证资质，可以承接相关项目。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-17/doc-inhccnef9221279.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-17/doc-inhccnef9221279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06127","603127","BK1576","BK1141","GLP","BK0216","BK4590","BK4144"],"gpt_icon":0},{"id":"2592911050","title":"Veru獲准將其試驗性減肥藥與GLP-1藥物聯合使用進行試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2592911050","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592911050?lang=zh_tw&edition=fundamental","pubTime":"2025-12-17 21:57","pubTimestamp":1765979820,"startTime":"0","endTime":"0","summary":"药物开发商Veru于12月17日宣称，已获美国食品和药物管理局（FDA）支持，获准开展一项新试验，即将其试验性肥胖症药物enobosarm与当下流行的GLP-1药物进行联合用药试验。这一决定意味着enobosarm在肥胖症治疗领域的探索迈出重要一步，通过与GLP-1药物联合，有望发挥协同作用，为肥胖症患者提供更有效的治疗方案。Veru公司计划于明年初正式启动这项新的中期试验，以进一步评估联合用药的安全性、有效性及最佳剂量等关键指标，试验结果或将对肥胖症治疗领域产生重要影响，为众多患者带来新的治疗希望。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217215914a6ae55e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217215914a6ae55e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4557","BK4007","VERU","GLP","BK4183","BK4590","BK4584","BK4144"],"gpt_icon":0},{"id":"2592968552","title":"GLP-1賽道激戰正酣：雙靶點、口服藥引領迭代潮，千億市場掘金圖譜全解析","url":"https://stock-news.laohu8.com/highlight/detail?id=2592968552","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592968552?lang=zh_tw&edition=fundamental","pubTime":"2025-12-17 11:25","pubTimestamp":1765941915,"startTime":"0","endTime":"0","summary":"慧博投研近日发布研究报告，对GLP-1（胰高血糖素样肽-1）行业进行了全面深度梳理。报告指出，GLP-1作为一种具有多重代谢调节功能的肠促胰素，已成为糖尿病、肥胖及相关代谢疾病治疗的核心靶点，其行业正经历快速迭代与市场扩容。报告核心内容包括以下几个方面：行业基础与市场格局：GLP-1通过刺激胰岛素分泌、抑制食欲等多重机制发挥疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://biz.eastmoney.com/a/202512173594052153.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4590","GLP","BK4144"],"gpt_icon":0},{"id":"2591078605","title":"GLP-1賽道或再擴容！信達生物瑪仕度肽青少年Ib期臨牀研究達主要終點 搶灘百億減重市場","url":"https://stock-news.laohu8.com/highlight/detail?id=2591078605","media":"蓝鲸新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591078605?lang=zh_tw&edition=fundamental","pubTime":"2025-12-16 14:54","pubTimestamp":1765868082,"startTime":"0","endTime":"0","summary":"【GLP-1赛道或再扩容！信达生物玛仕度肽青少年Ib期临床研究达主要终点 抢滩百亿减重市场】国内尚无任何儿童、青少年减重药物获批。信达生物GCG／GLP-1双受体激动剂玛仕度肽开始拓展青少年肥胖人群适应症。近日，信达生物公告，玛仕度肽在中国青少年肥胖人群中的Ib期临床研究达到主要终点。信达方面表示，基于该Ib期积极的安全性和疗效结果，信达生物计划于近期启动一项在青少年肥胖或超重参与者中的注册临床III期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512163592954568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","LU2242644610.SGD","GLP","LU2097828557.USD","BK1161","LU1969619763.USD","BK1583","LU0502904849.HKD","BK4590","BK1589","HK0000165453.HKD","BK4144","LU2097828474.EUR","LU0455707207.USD","LU2097828631.EUR","LU2328871848.SGD","LU2097828805.USD","01801","LU2097828714.EUR"],"gpt_icon":0},{"id":"2591966754","title":"中國藥企口服 GLP-1 超 20 億美元授權輝瑞；正大天晴全球首個 CDK2/4/6 抑制劑獲批上市｜Insight 新藥週報","url":"https://stock-news.laohu8.com/highlight/detail?id=2591966754","media":"丁香园 Insight 数据库","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591966754?lang=zh_tw&edition=fundamental","pubTime":"2025-12-14 13:48","pubTimestamp":1765691311,"startTime":"0","endTime":"0","summary":"伊奈利珠单抗本次gMG 新适应症的获批主要基于其全球关键性 Ⅲ 期试验 MINT 的积极结果。其中 MuSK+组随访 26 周，AChR+组随访 52 周。该申请此前已获 FDA 优先审查资格。临床试验动态1、德睿智药：口服小分子 GLP-1 首次启动 III 期临床12 月 10 日，德睿智药在 ClinicalTrials 官网登记了一项MDR-001 针对肥胖或超重受试者的 III 期临床。公开资料显示，这是该药启动的首个 III 期。该临床试验的目标是确定口服药物 MDR-001 是否能够改善超重或肥胖成年参与者的体重管理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214135346a4493885&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214135346a4493885&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4533","BK4599","LU0321505439.SGD","IE00BLSP4239.USD","BK4585","PFE","LU0306807586.USD","SG9999013999.USD","IE00BLSP4452.SGD","LU0306806265.USD","LU0225771236.USD","BK4007","LU1023059063.AUD","LU1057294990.SGD","BK4568","LU1894683264.USD","LU0868494617.USD","BK4592","LU0985481810.HKD","BK4550","IE00BBT3K403.USD","LU0234572021.USD","SGXZ57979304.SGD","SG9999011175.SGD","LU1066053197.SGD","BK4144","IE0002270589.USD","LU0321505868.SGD","IE00B19Z3581.USD","SG9999001176.SGD","SG9999001176.USD","SG9999002232.USD","SG9999003800.SGD","SG9999002224.SGD","BK4588","LU0122379950.USD","GLP","LU1883839398.USD","BK4581","LU0289739699.SGD","BK4534","IE000M9KFDE8.USD","LU0225284248.USD","LU1894683348.USD","LU0456855351.SGD","LU0170899867.USD","LU1066051498.USD","IE00B19Z3B42.SGD","BK4590","LU0058720904.USD"],"gpt_icon":1},{"id":"2590574050","title":"碧生源(00926)加碼投資ERX維持3%持股 支持非GLP-1減肥療法創新研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2590574050","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590574050?lang=zh_tw&edition=fundamental","pubTime":"2025-12-12 17:27","pubTimestamp":1765531670,"startTime":"0","endTime":"0","summary":"于投资及本公告日期，ERX及其最终实益拥有人各自独立于公司及其关连人士。为防止摊薄进一步侵蚀其投资价值，于2025年12月12日，董事会决议参与是次增资，以维持其于ERX现有约3%持股量。进一步投资彰显董事会对ERX的长期战略及未来前景继续充满信心，以及其对保护及提升公司经济利益的承诺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380929.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GLP","ERX","BK4590","BK4144","BK1237","00926"],"gpt_icon":0},{"id":"2590856846","title":"悦康藥業宋更申：GLP-1類藥物減肥或致抑鬱，被稱為「戒斷七情六慾的藥」","url":"https://stock-news.laohu8.com/highlight/detail?id=2590856846","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590856846?lang=zh_tw&edition=fundamental","pubTime":"2025-12-11 10:25","pubTimestamp":1765419900,"startTime":"0","endTime":"0","summary":"　　“2025中国企业竞争力年会”于12月9日至10日在北京举行，悦康药业集团股份有限公司董事、药物研究院院长宋更申在演讲中表示，减重领域正迎来市场爆发期。“国外多篇高分学术论文已明确揭示，GLP-1类药物可能导致使用者出现抑郁、情绪低落等问题，甚至被形象地称为戒断七情六欲的药。”","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2025-12-11/doc-inhakwap8304047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GLP","BK4590","BK0239","688658","BK4144"],"gpt_icon":0},{"id":"2589896048","title":"石藥集團(01093)：GLP-1/GIP受體雙偏向性激動多肽注射液在美國獲臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589896048","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589896048?lang=zh_tw&edition=fundamental","pubTime":"2025-12-05 18:55","pubTimestamp":1764932156,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的GLP-1/GIP受体双偏向性激动多肽注射液(该产品)已获得美国食品药品监督管理局批准，可在美国开展临床试验。该产品有望成为中国首款进入临床阶段的GLP-1/GIP受体双偏向激动剂，可选择性激活cAMP通路，显着降低β-arrestin募集，从而减少受体内吞及脱敏，提高药效和效果持续性。非人灵长类重复给药毒理研究显示，该产品耐受性良好，未观察到任何呕吐及胃肠道不良反应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378277.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B543WZ88.USD","LU1226287792.SGD","LU2039709279.SGD","LU1226288253.USD","BK1191","IE0008369823.USD","LU0315179316.USD","IE0008368742.USD","LU0072913022.USD","BK4590","LU0880133367.SGD","IE00BZ08YR35.GBP","BK4144","LU1152091168.USD","IE00B5MMRT66.SGD","LU1993786604.SGD","GLP","LU1152091754.HKD","LU0140636845.USD","IE00BZ08YT58.USD","LU1226287875.USD","LU1328277881.USD","LU1226287529.USD","BK1521","LU1807302812.USD","HK0000165453.HKD","SG9999004220.SGD","LU0067412154.USD","LU1960683339.HKD","LU0326950275.SGD","LU0314109678.HKD","LU1226288170.HKD","BK1515","IE00BZ08YS42.EUR","LU0501845795.SGD","IE00B031HY20.USD","LU1008478684.HKD","LU1951186391.HKD","01093","LU1813983027.USD"],"gpt_icon":0},{"id":"2588988906","title":"司美格魯肽等GLP-1藥物寫入WHO全球指南用於肥胖症治療","url":"https://stock-news.laohu8.com/highlight/detail?id=2588988906","media":"21财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588988906?lang=zh_tw&edition=fundamental","pubTime":"2025-12-04 20:01","pubTimestamp":1764849707,"startTime":"0","endTime":"0","summary":"为应对全球日益严峻的肥胖健康挑战，近日，世界卫生组织发布了首个关于将胰高血糖素样肽-1类药物用于治疗肥胖的全球指南。2025年9月，世卫组织已将GLP-1类药物纳入《基本药物目录》，用于高风险人群的2型糖尿病管理。此次新指南对GLP-1药物用于肥胖治疗提出了有条件的推荐，强调应将其作为包括健康饮食、规律运动和专业医务工作者健康指导在内的综合管理方案的一部分。新指南有助于降低因肥胖及其并发症带来的医疗成本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204200204a723bda3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204200204a723bda3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4590","IE00BZ1G4Q59.USD","BK4007","LU0154236417.USD","NVO","BK4585","LU1093756325.SGD","LU1093756168.USD","BK4588","IE00BKVL7J92.USD","GLP","BK4144","BK4599","BK4532"],"gpt_icon":1},{"id":"2588007417","title":"中國生物製藥(01177)：TQF3250「口服偏向型GLP-1受體激動劑」臨牀試驗申請獲NMPA、FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2588007417","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588007417?lang=zh_tw&edition=fundamental","pubTime":"2025-12-04 17:27","pubTimestamp":1764840424,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团自主研发的创新药TQF3250胶囊“口服偏向型GLP-1受体激动剂”的临床试验申请已获得中国国家药品监督管理局和美国食品药品监督管理局的批准，拟用于减重。TQF3250是一款口服小分子偏向型GLP-1受体激动剂。与传统GLP-1药物相比，TQF3250通过选择性激活cAMP偏向的GLP-1受体信号通路，促进胰岛素分泌，同时减少β-arrestin募集和受体内吞，从而延长药效持续时间。除减重适应症外，TQF3250用于治疗2型糖尿病的临床试验申请已获NMPA批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4590","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","BK1515","IE00BZ08YS42.EUR","BK1191","BK4144","01177","BK1521","HK0000165453.HKD","BK1589","GLP"],"gpt_icon":0},{"id":"1160145101","title":"漢堡王準備迎接GLP-1的變化","url":"https://stock-news.laohu8.com/highlight/detail?id=1160145101","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160145101?lang=zh_tw&edition=fundamental","pubTime":"2025-12-03 22:17","pubTimestamp":1764771426,"startTime":"0","endTime":"0","summary":"餐饮行业高管正在关注美国人使用GLP-1减肥药物后销售放缓的迹象，但汉堡王的母公司餐饮品牌国际（Restaurant Brands International）表示，他们已经做好了应对需求变化的准备。首席执行官Josh Kobza在一次投资者活动中表示，减肥药用户在使用这些药物时通常会寻求高蛋白食品，而汉堡王的产品富含蛋白质。Kobza表示，该连锁店的双层奶酪汉堡尺寸较小，肉与面包的比例高，非常适合GLP-1用户的需求。\n","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QSR","BK4144","GLP","BK4209","BK4590"],"gpt_icon":0},{"id":"2588083700","title":"司美格魯肽全球熱銷催生百億市場：國內30+企業激戰GLP-1賽道，2025年產能格局全解析","url":"https://stock-news.laohu8.com/highlight/detail?id=2588083700","media":"摩熵医药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588083700?lang=zh_tw&edition=fundamental","pubTime":"2025-12-02 11:03","pubTimestamp":1764644595,"startTime":"0","endTime":"0","summary":"可见其销量持续面临供不应求的局面。本文将系统梳理当前国内主要企业的现有产能、扩建进展及未来规划，全景呈现2025年司美格鲁肽原料药的产能格局。国内司美格鲁肽原料药产能布局截至2025年，国内已有超30家企业完成或规划相关产线布局，涵盖化学合成、固相多肽合成、发酵法等多种技术路径。总结总体来看，国内司美格鲁肽原料药的产能布局已然铺开，这场围绕GLP-1赛道的投入无疑是坚决的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202110355a4c705d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202110355a4c705d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU0154236417.USD","LU1093756168.USD","BK4007","BK4585","IE00BZ1G4Q59.USD","GLP","IE00BKVL7J92.USD","BK4599","02566","NVO","BK4532","BK4144","LU1093756325.SGD","BK4590"],"gpt_icon":1},{"id":"2588746896","title":"Grvt GLP 策略重新開放，資金上限提升至 750 萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588746896","media":"BitPush","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588746896?lang=zh_tw&edition=fundamental","pubTime":"2025-12-01 13:34","pubTimestamp":1764567255,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bitpush.news//articles/7592150","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bit_push_live","symbols":["GLP","BK4144","BK4590"],"gpt_icon":0},{"id":"2587962791","title":"歌禮制藥-B(01672)選定其首款口服GLP-1R/GIPR/GCGR三靶點激動劑多肽ASC37進行臨牀開發","url":"https://stock-news.laohu8.com/highlight/detail?id=2587962791","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587962791?lang=zh_tw&edition=fundamental","pubTime":"2025-11-30 18:35","pubTimestamp":1764498935,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，已选定其首款口服GLP-1R/GIPR/GCGR三靶点激动剂多肽ASC37口服片作为临床开发候选药物。体外实验显示，在对GLP-1R、GIPR和GCGR的激动活性方面，ASC37比retatrutide分别强约5倍、4倍和4倍。“选定ASC37，一款前景广阔的口服GLP-1R/GIPR/GCGR三靶点激动剂多肽，进行临床开发再次印证了我们强大的研发能力，也彰显了我们致力于解决肥胖症治疗领域未满足需求的坚定决心。”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","BK4160","01672","01477","GIPR","BK1515","BK4590","BK1191","BK4144","GLP"],"gpt_icon":0},{"id":"2586218492","title":"從注射到口服 GLP-1減肥藥進入下一時代","url":"https://stock-news.laohu8.com/highlight/detail?id=2586218492","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586218492?lang=zh_tw&edition=fundamental","pubTime":"2025-11-28 00:05","pubTimestamp":1764259500,"startTime":"0","endTime":"0","summary":"Ozempic及其代表的一类减肥药，其影响似乎无处不在：惠及数百万减重效果空前的患者；推动杂货店货架涌现专为用药人群设计的新产品；甚至被保险公司纳入死亡率影响研究范畴。　　尽管GLP-1药物引发了诸多社会变革，但高昂的价格限制了其可及性。许多患者在出现不良反应后停药，另有部分潜在受益人群因不愿接受注射而望而却步。　　市场对口服减重药的期待极高，它们已被纳入与白宫的药品价格谈判。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-11-28/doc-infywkcv0535366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GLP","BK4144","BK4590"],"gpt_icon":0},{"id":"2586228902","title":"禮來模式揭秘：GLP-1，AI 加速藥物發現，禮來如何突破「創新者窘境」？","url":"https://stock-news.laohu8.com/highlight/detail?id=2586228902","media":"海外独角兽","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586228902?lang=zh_tw&edition=fundamental","pubTime":"2025-11-27 20:01","pubTimestamp":1764244906,"startTime":"0","endTime":"0","summary":"如今礼来市值逼近万亿，已大幅领先其他制药公司，而推动这一跃升的核心力量正是突破性的 GLP-1 药物。礼来正处于 GLP-1 早期增长阶段，有很大增长空间，今年截至目前的收入增长率已达到 40%。礼来公司在 20 世纪率先大规模生产胰岛素，如今凭借新型 GLP-1 糖尿病和减肥药成为市场领导者。随着仿制药上市，GLP-1 预计将覆盖超过 4000 万成年人，规模将超过当前使用他汀类药物的人数。完全由 AI 驱动的药物尚未进入临床，但相关成果正在逐步出现。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127202742a7154a55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127202742a7154a55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999001176.SGD","LU1291159041.SGD","BK4581","IE00BK4W5L77.USD","LU0203202063.USD","LU0353189680.USD","LU1127390331.HKD","LU0203201768.USD","SG9999015986.USD","LU1623119135.USD","GLP","LU2106854487.HKD","LU0882574139.USD","LU2361044865.SGD","LU2168564149.EUR","SG9999018857.SGD","LU1551013425.SGD","LU0417517546.SGD","LU2168564222.USD","LU2361044949.HKD","LU2746668974.SGD","IE00B2B36J28.USD","SG9999013999.USD","LU0106261372.USD","IE00BK4W5M84.HKD","LLY","SGXZ51526630.SGD","LU0079474960.USD","LU0471298777.SGD","LU2746668461.USD","LU1023059063.AUD","LU1917777945.USD","LU2168564065.EUR","LU1035775433.USD","LU1983299246.USD","LU1720051017.SGD","LU1868836757.USD","LU1061106388.HKD","SG9999017495.SGD","LU2462157665.USD","IE0009355771.USD","LU1804176565.USD","LU0122379950.USD","LU0266013472.USD","SG9999014914.USD","LU2168564495.EUR","IE00BKPKM429.USD","SG9999014906.USD","LU0320765992.SGD","LU2168563687.JPY"],"gpt_icon":1},{"id":"2586377182","title":"全球首個基礎胰島素GLP-1RA周製劑Kyinsu歐盟獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2586377182","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586377182?lang=zh_tw&edition=fundamental","pubTime":"2025-11-26 17:20","pubTimestamp":1764148840,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["GLP","FSXEmain","BK4590","BK4144","FESXmain"],"gpt_icon":0},{"id":"2586464854","title":"諾和諾德 GLP-1 折戟阿爾茨海默病，渤健 Leqembi 迎來競爭利好","url":"https://stock-news.laohu8.com/highlight/detail?id=2586464854","media":"抗体圈","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586464854?lang=zh_tw&edition=fundamental","pubTime":"2025-11-25 12:02","pubTimestamp":1764043353,"startTime":"0","endTime":"0","summary":"诺和诺德 GLP-1 失利，渤健压力解除阿尔茨海默病被视作最难攻克的神经退行性疾病之一，过去数十年间，绝大多数疗法研发均以失败告终。11 月，诺和诺德公布的 EVOKE 与 EVOKE + 两项 III 期试验结果显示，其明星 GLP-1 药物司美格鲁肽无法减缓阿尔茨海默病病程进展，这一结果让原本被视作潜在竞争者的 GLP-1 类药物暂时退出该领域角逐。此外，渤健还在等待 FDA 对 Leqembi 皮下诱导剂型的审批，杰富瑞预计审批结果将于 2026 年年中落地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251125130311a70fc243&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251125130311a70fc243&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GLP","NVO","LU0154236417.USD","BK4585","IE00BKVL7J92.USD","BK4590","BK4007","BK4532","BK4588","LU1093756325.SGD","LU1093756168.USD","BK4599","IE00BZ1G4Q59.USD","BK4144"],"gpt_icon":1},{"id":"2584990441","title":"派格生物首個產品獲批，GLP-1賽道已有16個玩家；復宏漢霖HLX43啓動II期臨牀，適應證為胰腺導管腺癌 | 掘金創新藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2584990441","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584990441?lang=zh_tw&edition=fundamental","pubTime":"2025-11-19 14:52","pubTimestamp":1763535135,"startTime":"0","endTime":"0","summary":"一周行情11月10日至11月14日，医药生物指数上涨2.19%，跑赢上证指数2.65个百分点，结束近2个月的低迷行情。创新药（BK1106）周内上涨4.93%；恒生医疗保健业指数（HSCICH）周内上涨7.18%；港股创新药ETF（513120）周内上涨5.90%。一周点评上周医药板块结束调整强势反弹，创新药及港股医疗表现尤为亮眼，显示市场对政策担忧有所缓解，风险偏好显著回升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511193568713864.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511193568713864.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","06978","BK1161","HK0000165453.HKD","02696","BK4590","BK4144","GLP"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":1,"totalSize":176,"code":"91000000","status":"200"}]}}